Response to "Outcomes and costs associated with PHiD-CV, a new protein D conjugate pneumococcal vaccine, in four countries"

Vaccine

Volumn 29, Issue 44, 2011, Pages 7589-7590

  Strutton, David ^a   Hwang, Sharon ^a   Farkouh, Raymond ^a   Roberts, Craig ^a  

^a PFIZER INC   (United States)

Author keywords

Cost effectiveness; Cross protection; Pneumococcal conjugate vaccine; Prevenar; Prevenar 13

Indexed keywords

BACTERIAL PROTEIN; PNEUMOCOCCUS VACCINE; POET VACCINE; PROTEIN D; UNCLASSIFIED DRUG;

ACUTE OTITIS MEDIA; CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; CROSS PROTECTION; DRUG ANTIGENICITY; DRUG DOSE REGIMEN; HAEMOPHILUS INFLUENZAE; HUMAN; LETTER; MYRINGOTOMY; OUTCOME ASSESSMENT; PNEUMOCOCCAL INFECTION; PNEUMONIA; PRIORITY JOURNAL;

FEMALE; HUMANS; MALE; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES;

EID: 80051671397     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.02.103     Document Type: Letter

References (21)

1. Talbird S.E., Taylor T.N., Knoll S., Frostad C.R., Martí SG Outcomes and costs associated with PHiD-CV, a new protein D conjugate pneumococcal vaccine, in four countries. Vaccine 2010, 28(Suppl. 6):G23-G29.
2. Chuck A.W., Jacobs P., Tyrrell G., Kellner J.D. Pharmacoeconomic evaluation of 10- and 13-valent pneumococcal conjugate vaccines. Vaccine 2010, 28(33):5485-5490.
3. Vesikari T., Wysocki J., Chevallier B., Karvonen A., Czajka H., Ars̈ne J.-P., et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatric Infectious Disease Journal 2009, 28(4):S66-S76. 10.1097/INF.0b013e318199f8ef.
4. Prymula R., Peeters P., Chrobok V., Kriz P., Novakova E., Kaliskova E., et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 2006, 367(March (9512)):740-748.
5. Eskola J., Kilpi T., Palmu A., Jokinen J., Haapakoski J., Herva E., et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. New England Journal of Medicine 2001, 344(February (6)):403-409.
6. EMEA Synflorix Summary of Product Characteristics.
7. Black S., Shinefield H., Fireman B., Lewis E., Ray P., Hansen J.R., et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatric Infectious Disease Journal 2000, 19(March (3)):187-195.
8. Pilishvili T., Lexau C., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. Journal of Infectious Diseases 2010, 201(January (1)):32-41.
9. Ardanuy C., Rolo D., Fenoll A., Tarrago D., Calatayud L., Linares J., et al. Emergence of a multidrug-resistant clone (ST320) among invasive serotype 19A pneumococci in Spain. Journal of Antimicrobial Chemotherapy 2009, 64(September (3)):507-510.
10. Kellner J.D., Vanderkooi O.G., MacDonald J., Church D.L., Tyrrell G.J., Scheifele D.W. Changing epidemiology of invasive pneumococcal disease in Canada, 1998-2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study. Clinical Infectious Diseases 2009, 49(July (2)):205-212.
11. Mahjoub-Messai F., Doit C., Koeck J.-L., Billard T., Evrard B., Bidet P., et al. Population snapshot of Streptococcus pneumoniae serotype 19A isolates before and after introduction of seven-valent pneumococcal vaccination for French children. Journal of Clinical Microbiology 2009, 47(March (3)):837-840.
12. Kieninger D.M., Kueper K., Steul K., Juergens C., Ahlers N., Baker S., et al. Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany. Vaccine 2010, 28(June (25)):4192-4203.
13. Yeh S.H., Gurtman A., Hurley D.C., Block S.L., Schwartz R.H., Patterson S., et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers. Pediatrics 2010, 126(September (3)):e493-e505.
14. O'Brien K.L., Moisi J., Moulton L.H., Madore D., Eick A., Reid R., et al. Predictors of pneumococcal conjugate vaccine immunogenicity among infants and toddlers in an American Indian PnCRM7 efficacy trial. Journal of Infectious Diseases 2007, 196(July (1)):104-114.
15. Park S.Y., Moore M.R., Bruden D.L., Hyde T.B., Reasonover A.L., Harker-Jones M., et al. Impact of conjugate vaccine on transmission of antimicrobial-resistant Streptococcus pneumoniae among Alaskan children. Pediatric Infectious Disease Journal 2008, 27(April (4)):335-340.
16. Grivea I.N., Panagiotou M., Tsantouli A.G., Syrogiannopoulos GA Impact of heptavalent pneumococcal conjugate vaccine on nasopharyngeal carriage of penicillin-resistant Streptococcus pneumoniae among day-care center attendees in central Greece. Pediatric Infectious Disease Journal 2008, 27(June (6)):519-525.
17. Huang S.S., Hinrichsen V.L., Stevenson A.E., Rifas-Shiman S.L., Kleinman K., Pelton S.I., et al. Continued impact of pneumococcal conjugate vaccine on carriage in young children. Pediatrics 2009, 124(July (1)):e1-e11.
18. Whitney C.G., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., Lynfield R., et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. New England Journal of Medicine 2003, 348(May (18)):1737-1746.
19. Prymula R., Kriz P., Kaliskova E., Pascal T., Poolman J., Schuerman L. Effect of vaccination with pneumococcal capsular polysaccharides conjugated to Haemophilus influenzae-derived protein D on nasopharyngeal carriage of Streptococcus pneumoniae and H. influenzae in children under 2 years of age. Vaccine 2009, 28(1):71-78.
20. Silfverdal S.A., Hogh B., Bergsaker M.R., Skerlikova H., Lommel P., Borys D., et al. Immunogenicity of a 2-dose priming and booster vaccination with the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine. Pediatric Infectious Disease Journal 2009, 28(October (10)):e276-e282.
21. Rozenbaum M.H., Sanders E.A., van Hoek A.J., Jansen A.G., van der Ende A., van den Dobbelsteen G., et al. Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines. BMJ 2010, 340:c2509.